Gal-3参与阿尔茨海默病的机制研究进展

doi:10.11958/20220639

摘要/Abstract

摘要：

半乳糖凝集素-3（Gal-3）属半乳糖苷凝集素家族,表达于神经系统,可结合多种分子,通过调节下游信号发挥作用。在阿尔茨海默病（AD）患者的病变脑区、血清和脑脊液中,Gal-3的表达变化与AD病变进程相关。因此,Gal-3有望成为AD诊断与检测药物疗效的重要生物标志物。该文就Gal-3参与AD的分子机制研究进展进行综述,以期为AD的诊断、治疗及药物研发提供新观点。

关键词: 阿尔茨海默病, 半乳糖凝集素3, 炎症, 淀粉样β肽类, 小神经胶质细胞

Abstract:

Galectin-3 (Gal-3), widely expressed in central nervous system, is a member of the galectin family. Gal-3 can bind a variety of molecules and play a role by regulating downstream signals. Recent advances have suggested that changes in Gal-3 expression in brain tissues, serum and cerebrospinal fluid of patients with Alzheimer's disease (AD) are closely related to the severity of AD. Therefore, GAL-3 is expected to be an important biomarker for the diagnosis and detection of drug efficacy in AD. In this review, we present an updated overview of the current understanding of Gal-3 involvement in AD, which may provide useful references for the clinical diagnosis and treatment of AD in the future.

Key words: Alzheimer disease, Galectin 3, inflammation, amyloid beta-peptides, microglia

中图分类号:

R338.2

参考文献 49

[1]	GAO Z, LIU Z, WANG R, et al. Galectin-3 is a potential mediator for atherosclerosis[J]. J Immunol Res, 2020, 2020:5284728. doi: 10.1155/2020/5284728.
[2]	BLANDA V, BRACALE U M, DI TARANTO M D, et al. Galectin-3 in cardiovascular diseases[J]. Int J Mol Sci, 2020, 21(23):9232. doi: 10.3390/ijms21239232.
[3]	TAN Y, ZHENG Y, XU D, et al. Galectin-3:A key player in microglia-mediated neuroinflammation and Alzheimer's disease[J]. Cell Biosci, 2021, 11(1):78. doi: 10.1186/s13578-021-00592-7.
[4]	李志刚, 林文弢. 半乳糖凝集素3:治疗代谢综合征及相关疾病的新靶点[J]. 生命的化学, 2017, 37(6):907-912.
	LI Z G, LIN W T. Galectin-3:A new target for the treatment of metabolic syndrome-related diseases[J]. Chem Life, 2017, 37(6):907-912. doi: 10.13488/j.smhx.20170605.
[5]	SUTHAHAR N, MEIJERS W C, SILLJÉ H, et al. Galectin-3 activation and inhibition in heart failure and cardiovascular disease:An update[J]. Theranostics, 2018, 8(3):593-609. doi: 10.7150/thno.22196.
[6]	NANGIA-MAKKER P, HOGAN V, RAZ A. Galectin-3 and cancer stemness[J]. Glycobiology, 2018, 28(4):172-181. doi: 10.1093/glycob/cwy001.
[7]	THOMAS L, PASQUINI L A. Galectin-3-mediated glial crosstalk drives oligodendrocyte differentiation and(Re)myelination[J]. Front Cell Neurosci, 2018, 12:297. doi: 10.3389/fncel.2018.00297.
[8]	IMAI S, KOYANAGI M, AZIMI Z, et al. Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms[J]. Sci Rep, 2017, 7(1):5947. doi: 10.1038/s41598-017-05784-1.
[9]	TAKAKU S, YANAGISAWA H, WATABE K, et al. GDNF promotes neurite outgrowth and upregulates galectin-1 through the RET/PI3K signaling in cultured adult rat dorsal root ganglion neurons[J]. Neurochem Int, 2013, 62(3):330-339. doi: 10.1016/j.neuint.2013.01.008.
[10]	ESPOSITO N J, MAZZONI F, VARGAS J A, et al. Diurnal photoreceptor outer segment renewal in mice is independent of Galectin-3[J]. Invest Ophthalmol Vis Sci, 2021, 62(2):7. doi: 10.1167/iovs.62.2.7.
[11]	MENDONÇA H R, CARVALHO J, ABREU C A, et al. Lack of Galectin-3 attenuates neuroinflammation and protects the retina and optic nerve of diabetic mice[J]. Brain Res, 2018, 1700:126-137. doi: 10.1016/j.brainres.2018.07.018.
[12]	YOO H I, KIM E G, LEE E J, et al. Neuroanatomical distribution of galectin-3 in the adult rat brain[J]. J Mol Histol, 2017, 48(2):133-146. doi: 10.1007/s10735-017-9712-9.
[13]	REN Z, LIANG W, SHENG J, et al. Gal-3 is a potential biomarker for spinal cord injury and Gal-3 deficiency attenuates neuroinflammation through ROS/TXNIP/NLRP3 signaling pathway[J]. Biosci Rep, 2019, 39(12):BSR20192368. doi: 10.1042/BSR20192368.
[14]	NOMURA K, VILALTA A, ALLENDORF D H, et al. Activated microglia desialylate and phagocytose cells via neuraminidase,Galectin-3,and mer tyrosine kinase[J]. J Immunol, 2017, 198(12):4792-4801. doi: 10.4049/jimmunol.1502532.
[15]	SALEH A, MARHUENDA E, FABRE C, et al. A novel 3D nanofibre scaffold conserves the plasticity of glioblastoma stem cell invasion by regulating galectin-3 and integrin-β1 expression[J]. Sci Rep, 2019, 9(1):14612. doi: 10.1038/s41598-019-51108-w.
[16]	WANG H, SONG X, HUANG Q, et al. LGALS3 promotes treatment resistance in glioblastoma and is associated with tumor risk and prognosis[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(4):760-769. doi: 10.1158/1055-9965.EPI-18-0638.
[17]	SREJOVIC I, SELAKOVIC D, JOVICIC N, et al. Galectin-3:Roles in neurodevelopment,neuroinflammation,and behavior[J]. Biomolecules, 2020, 10(5):798. doi: 10.3390/biom10050798.
[18]	SILVERMAN A M, NAKATA R, SHIMADA H, et al. A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma[J]. Cancer Res, 2012, 72(9):2228-2238. doi: 10.1158/0008-5472.CAN-11-2165.
[19]	XU G R, ZHANG C, YANG H X, et al. Modified citrus pectin ameliorates myocardial fibrosis and inflammation via suppressing galectin-3 and TLR4/MyD88/NF-κB signaling pathway[J]. Biomed Pharmacother, 2020, 126:110071. doi: 10.1016/j.biopha.2020.110071.
[20]	BOZA-SERRANO A, RUIZ R, SANCHEZ-VARO R, et al. Galectin-3,a novel endogenous TREM2 ligand,detrimentally regulates inflammatory response in alzheimer's disease[J]. Acta Neuropathol, 2019, 138(2):251-273. doi: 10.1007/s00401-019-02013-z.
[21]	MARGADANT C, VAN DEN BOUT I, VAN BOXTEL A L, et al. Epigenetic regulation of galectin-3 expression by β1 integrins promotes cell adhesion and migration[J]. J Biol Chem, 2012, 287(53):44684-44693. doi: 10.1074/jbc.M112.426445.
[22]	WESLEY U V, VEMUGANTI R, AYVACI E R, et al. Galectin-3 enhances angiogenic and migratory potential of microglial cells via modulation of integrin linked kinase signaling[J]. Brain Res, 2013, 1496:1-9. doi: 10.1016/j.brainres.2012.12.008.
[23]	DOS SANTOS S N, SHELDON H, PEREIRA J X, et al. Galectin-3 acts as an angiogenic switch to induce tumor angiogenesis via Jagged-1/Notch activation[J]. Oncotarget, 2017, 8(30):49484-49501. doi: 10.18632/oncotarget.17718.
[24]	LI P, LIU S, LU M, et al. Hematopoietic-derived Galectin-3 causes cellular and systemic insulin resistance[J]. Cell, 2016, 167(4):973-984.e12. doi: 10.1016/j.cell.2016.10.025.
[25]	AL-DALAHMAH O, CAMPOS SOARES L, NICHOLSON J, et al. Galectin-3 modulates postnatal subventricular zone gliogenesis[J]. Glia, 2020, 68(2):435-450. doi: 10.1002/glia.23730.
[26]	ZHANG L, WANG P, QIN Y, et al. RN1,a novel galectin-3 inhibitor,inhibits pancreatic cancer cell growth in vitro and in vivo via blocking galectin-3 associated signaling pathways[J]. Oncogene, 2017, 36(9):1297-1308. doi: 10.1038/onc.2016.306.
[27]	NAKAJIMA K, KHO D H, YANAGAWA T, et al. Galectin-3 cleavage alters bone remodeling:different outcomes in breast and prostate cancer skeletal metastasis[J]. Cancer Res, 2016, 76(6):1391-1402. doi: 10.1158/0008-5472.CAN-15-1793.
[28]	HU K, GU Y, LOU L, et al. Galectin-3 mediates bone marrow microenvironment-induced drug resistance in acute leukemia cells via Wnt/β-catenin signaling pathway[J]. J Hematol Oncol, 2015, 8:1. doi: 10.1186/s13045-014-0099-8.
[29]	HAFSIA N, FORIEN M, RENAUDIN F, et al. Galectin 3 deficiency alters chondrocyte primary cilium formation and exacerbates cartilage destruction via mitochondrial apoptosis[J]. Int J Mol Sci, 2020, 21(4):1486. doi: 10.3390/ijms21041486.
[30]	HARAZONO Y, NAKAJIMA K, RAZ A. Why anti-Bcl-2 clinical trials fail:A solution[J]. Cancer Metastasis Rev, 2014, 33(1):285-294. doi: 10.1007/s10555-013-9450-8.
[31]	AL-SALAM S, JAGADEESH G S, SUDHADEVI M, et al. Galectin-3 possesses anti-necroptotic and anti-apoptotic effects in cisplatin-induced acute tubular necrosis[J]. Cell Physiol Biochem, 2021, 55(3):344-363. doi: 10.33594/000000381.
[32]	SLACK R J, MILLS R, MACKINNON A C. The therapeutic potential of galectin-3 inhibition in fibrotic disease[J]. Int J Biochem Cell Biol, 2021, 130:105881. doi: 10.1016/j.biocel.2020.105881.
[33]	TROMPET S, JUKEMA W, MOOIJAART S P, et al. Genetic variation in galectin-3 gene associates with cognitive function at old age[J]. Neurobiol Aging, 2012, 33(9):2232.e1-2232.e9. doi: 10.1016/j.neurobiolaging.2012.05.001.
[34]	YAZAR T, OLGUN YAZAR H, CIHAN M. Evaluation of serum galectin-3 levels at Alzheimer patients by stages: A preliminary report[J]. Acta Neurol Belg, 2021, 121(4):949-954. doi: 10.1007/s13760-020-01477-1.
[35]	WANG X, ZHANG S, LIN F, et al. Elevated galectin-3 levels in the serum of patients with alzheimer's disease[J]. Am J Alzheimers Dis Other Demen, 2015, 30(8):729-732. doi: 10.1177/1533317513495107.
[36]	ASHRAF G M, BAEESA S S. Investigation of Gal-3 expression pattern in serum and cerebrospinal fluid of patients suffering from neurodegenerative disorders[J]. Front Neurosci, 2018, 12:430. doi: 10.3389/fnins.2018.00430.
[37]	TAO C C, CHENG K M, MA Y L, et al. Galectin-3 promotes Aβ oligomerization and Aβ toxicity in a mouse model of Alzheimer's disease[J]. Cell Death Differ, 2020, 27(1):192-209. doi: 10.1038/s41418-019-0348-z.
[38]	RAMíREZ E, SáNCHEZ-MALDONADO C, MAYORAL M A, et al. Neuroinflammation induced by the peptide amyloid-β(25-35)increase the presence of galectin-3 in astrocytes and microglia and impairs spatial memory[J]. Neuropeptides, 2019, 74:11-23. doi: 10.1016/j.npep.2019.02.001.
[39]	HALIM A, BRINKMALM G, RÜETSCHI U, et al. Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid beta-peptides in human cerebrospinal fluid[J]. Proc Natl Acad Sci U S A, 2011, 108(29):11848-11853. doi: 10.1073/pnas.1102664108.
[40]	SEKI T, KANAGAWA M, KOBAYASHI K, et al. Galectin 3-binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein[J]. J Biol Chem, 2020, 295(11):3678-3691. doi: 10.1074/jbc.RA119.008703.
[41]	HERRERA-RIVERO M, SANTARELLI F, BROSSERON F, et al. Dysregulation of TLR5 and TAM ligands in the Alzheimer's brain as contributors to disease progression[J]. Mol Neurobiol, 2019, 56(9):6539-6550. doi: 10.1007/s12035-019-1540-3.
[42]	KIM J Y, KIM D H, KIM D S, et al. Galectin-3 secreted by human umbilical cord blood-derived mesenchymal stem cells reduces amyloid-beta42 neurotoxicity in vitro[J]. FEBS Lett, 2010, 584(16):3601-3608. doi: 10.1016/j.febslet.2010.07.028.
[43]	DU H, WONG M Y, ZHANG T, et al. A multifaceted role of progranulin in regulating amyloid-beta dynamics and responses[J]. Life Sci Alliance, 2021, 4(7):e202000874. doi: 10.26508/lsa.202000874.
[44]	SHAROAR M G, PALKO S, GE Y, et al. Accumulation of saposin in dystrophic neurites is linked to impaired lysosomal functions in Alzheimer's disease brains[J]. Mol Neurodegener, 2021, 16(1):45. doi: 10.1186/s13024-021-00464-1.
[45]	OKU Y, MURAKAMI K, IRIE K, et al. Synthesized Aβ42 caused intracellular oxidative damage,leading to cell death,via lysosome rupture[J]. Cell Struct Funct, 2017, 42(1):71-79. doi: 10.1247/csf.17006.
[46]	LI Y, XU M, DING X, et al. Protein kinase C controls lysosome biogenesis independently of mTORC1[J]. Nat Cell Biol, 2016, 18(10):1065-1077. doi: 10.1038/ncb3407.
[47]	SHEEDY F J, GREBE A, RAYNER K J, et al. CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation[J]. Nat Immunol, 2013, 14(8):812-820. doi: 10.1038/ni.2639.
[48]	NISHIKAWA H, LIU L, NAKANO F, et al. Modified citrus pectin prevents blood-brain barrier disruption in mouse subarachnoid hemorrhage by inhibiting Galectin-3[J]. Stroke, 2018, 49(11):2743-2751. doi: 10.1161/STROKEAHA.118.021757.
[49]	YIN Q, CHEN J, MA S, et al. Pharmacological inhibition of Galectin-3 ameliorates diabetes-associated cognitive impairment,oxidative stress and neuroinflammation in vivo and in vitro[J]. J Inflamm Res, 2020, 13:533-542. doi: 10.2147/JIR.S273858.